NCT03054896View on ClinicalTrials.gov

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2027

Conditions
Richter Syndrome
Interventions
DRUG

Venetoclax

Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor

OTHER

DA-EPOCH-R

Intensive chemotherapy regiment

OTHER

R-CHOP

Intensive chemotherapy regiment

Trial Locations (3)

43210

Ohio State University, Columbus

77030

MD Anderson Cancer Center, Houston

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03054896 - A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome | Biotech Hunter | Biotech Hunter